Goldman Sachs: 'we expect GILD to continue to engage in strategic BD'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


